June 9, 2017 03:23 PM EDT
R&D

Tri­al ob­servers say ‘game over’ for XBiotech's failed PhI­II can­cer study, the lat­est in a long line of set­backs

John Carroll

Editor & Founder

There’s more bad news to re­port for XBiotech $XBIT.

A few weeks af­ter Eu­ro­pean reg­u­la­tors snubbed the com­pa­ny’s ap­pli­ca­tion to start mar­ket­ing its du­bi­ous …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Bio­phar­ma be­gins to con­tem­plate an RFK Jr.-in­flu­enced FDA if Trump wins

Pfiz­er shares new de­tails on obe­si­ty pipeline, hints at ‘oth­er op­por­tu­ni­ties’

GSK buys au­toim­mune T cell en­gager for $300M up­front from Chim­a­gen

No­var­tis takes $800M Mor­phoSys write­down mere months af­ter clos­ing ac­qui­si­tion

No­var­tis high­lights over­all M&A track record fol­low­ing Mor­phoSys im­pair­ment

Fol­low­ing March in­spec­tion, No­vo Nordisk's semaglu­tide man­u­fac­tur­ing fa­cil­i­ty cit­ed by FDA

A service from the Financial Times